bullish
China Population Policies Impact on Healthcare Companies Series – Part 4
2.1k Views19 Apr 2024 09:16
SUMMARY
- Entering 2024, more provinces/regions have included assisted reproductive medical service projects into medical insurance reimbursement scope. It is expected that the government will accelerate the introduction of supporting measures ahead.
- Livzon’s performance in 2023 was disappointing.For BGI, even if the BIOSECURE Act passes and BGI is sanctioned by the US, the overall impact on the company is limited and controllable.
- Jinxin has gradually recovered from the negative impact of COVID-19.With the recovery of international flights and the increase in the number of patients, the Company would be back on track.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Population Policies Impact on Healthcare Companies Series – Part 419 Apr 2024
- China Population Policies Impact on Healthcare Companies Series - Part 305 Jan 2024
- China Population Policies Impact on Healthcare Companies Series – Part 203 Oct 2023
- China Population Policies Impact on Healthcare Companies Series - Part 118 Jul 2023
x